ClinicalTrials.gg
Status unknownNCT05233202LEONARDUpdated May 15, 2023

Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction

A Phase 3 interventional study of Levosimendan and PLACEBO in Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid, sponsored by Assistance Publique - Hôpitaux de Paris. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Prospective, multicenter, randomized (two arms, parallel groups); double-blind, placebo-controlled in order to assess the ability of preoperative levosimendan to prevent post-operative low cardiac output in high-risk patients referred to cardiac surgery for correcting functional tricuspid regurgitation. The primary end point is a composite element that includes peri-operative mortality and low cardiac output syndrome at day-90: 1) catecholamine infusion persisting beyond 48 hours after cardiac surgery, 2) the need for circulatory mechanical assist devices in the postoperative period, 3) or the need for renal replacement therapy at any time during intensive care unit stay. If a patient had at least 1 of these criteria, he or she was considered as meeting the primary end point.The secondary end points were 1) each component of the primary end point, and 2) the study drug safety defined as refractory hypotension.

Read the detailed description

Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid are randomized in 2 arms, the levosimendan group or to the placebo group.

In the experimental group, levosimendan is administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.

In the comparator group, Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin \<48H before anesthetic induction

02

Conditions studied

  • Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,039 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation [effective regurgitant orifice (ERO)>20mm², or systolic hepatic vein flow blunting or reversal]
  • Written signed
  • Affiliation to the French health care system (Sécurité Sociale)

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Severe organic renal dysfunction defined by \<30mL/min
  • Recent endocarditis (\<3 months)
  • Recent myocardial infarction (\<3 months)
  • Tricuspid valve perforation or prolapse
  • Cardiogenic shock requiring dobutamine support or cardiac assistance
  • Severe liver injury (CHILD C)
  • Left ventricular obstruction
  • Allergy to levosimedan
  • Current participation in other drug or device studies or being in the exclusion period at the end of a previous study involving human participants, if applicable
  • Pregnant or breastfeeding women
  • Females of without effective method of
  • Patient on AME (state medical aid) unless exemption from affiliation
  • Hypotension with SBP\<90mmHg
  • Severe tachycardia
  • History of torsade de pointe
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    LEVOSIMEDAN

    Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.

    Drug: Levosimendan

  • Placebo comparator
    PLACEBO

    Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin \<48H before anesthetic induction.

    Drug: PLACEBO

Interventions

  • Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.

    Also known as: Experimental arm

  • DrugPLACEBO

    Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin \<48H before anesthetic induction.

    Also known as: Control arm

06

What researchers measure

Primary outcomes

  1. Evaluate the effects of CTAC on ventilation/perfusion ratios during a moderate to severe ARDS

    The primary end point is a composite element that includes peri-operative mortality and low cardiac output syndrome at day-90: 1) catecholamine infusion persisting beyond 48 hours after cardiac surgery, 2) the need for circulatory mechanical assist devices in the postoperative period, 3) or the need for renal replacement therapy at any time during intensive care unit stay. If a patient had at least 1 of these criteria, he or she was considered as meeting the primary end point.

    Time frame: day 90

Secondary outcomes

  1. incidence of Refractory Hypotension (Drug safety)

    the study drug safety is defined as a refractory hypotension.

    Time frame: day 90

  2. Number of catecholamine infusion

    persistence of infusion beyond 48 hours after cardiac surgery

    Time frame: during 90 days

  3. Number of circulatory mechanical assist devices

    the need of circulatory mechanical assist devices in the postoperative period

    Time frame: during 90 days

  4. Number of renal replacement therapy

    Need for renal replacement therapy at any time during intensive care unit stay

    Time frame: during 90 days

07

Study locations

1 of 1 sites recruiting
  • Assistance Publique Hôpitaux de Paris-Hôpital Henri Mondor
    Créteil, 94000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Jan 2025, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2022
First posted
Feb 10, 2022
StartActual
Jan 23, 2023
Primary completionEst.
Jan 23, 2025
CompletionEst.
Jan 23, 2025
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05233202
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Jan 23, 2023
Primary completion
Jan 23, 2025 (estimated)
Completion
Jan 23, 2025 (estimated)
Last update
May 15, 2023

Study contacts

Pascal LIM, MD, PhD
Contact
pascal.lim@aphp.fr
(0)1.49.81.45.84 ext. 33
Akim SOUAG
Contact
akim.souag@aphp.fr
(0)1 44 84 17 15 ext. 33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simendan

Start the discussion